Table 3. End of Therapy of Hepatitis C patients treated with Ribavirin, Sofosbuvir and Interferon. *Mean± SD **N (%).
| EOT | Addict | Non-Addict | P value | |
|---|---|---|---|---|
| EOT and genotype | 1 | **17(68) | 24(75) | 0.001 |
| 2 | 0 (0) | 0 (0) | ||
| 3 | 8(32) | 8(25) | ||
| 4 | 0 (0) | 0 (0) | ||
| EOT | Male | 24(96) | 22(68.8) | 0.39 |
| female | 1(4) | 10(31.2) | ||
| Treatment of Hepatitis C with interferon and ribavirin regimen | 7 (28) | 12(37.5) | 0.001 | |
| ALT post – treatment | *45.6± 18.0 | 50.9 ± 56.44 | 0.96 | |
| AST post- treatment | 25.30 ± 20.48 | 28.87 ± 19.38 | 0.07 | |
| SVR | 25(100 ) | 31 (96.87) | 0.001 | |